Stocks · News reference
HC Wainwright & Co. Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $245
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 24, 2026, 10:21 AM
- Checked
- Aug 24, 2026, 1:28 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Inhibrx Biosciences, Inc. (INBX)
Filed: 2026-08-13 AccNo: 0002007919-26-000044 Size: 271 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarInhibrx Biosciences Says FDA Accepts BLA Seeking Approval Of Ozekibart In Patients With Conventional Chondrosarcoma; PDUFA Goal Date Set For April 14, 2027
Read original at benzinga